← All trials
NCT05992220
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2022
- Primary completion
- Mar 31, 2026
- Completion date
- Mar 31, 2026
- First posted
- Aug 15, 2023
- Last posted
- Aug 15, 2023
- Enrollment
- 138
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of UlsanLead sponsor
- Hanyang UniversityCollaborator
- Seoul National UniversityCollaborator
- University of UlsanOverall official - principal investigator
- University of UlsanReponsible party - principal investigator
- Soon Chun Hyang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.